Prothena Advances Lead Candidate to Phase 1 While Securing Cash Runway Into 2027
Prothena reported first quarter 2026 financial results and noted sufficient cash runway into 2027 to fund ongoing programs. The company advanced its lead immuno-neurology candidate into Phase 1 trials and secured a new collaboration for its amyloid-targeting research.
1. Q1 Financial Results
Prothena released its financial results for the first quarter of 2026, confirming a net loss consistent with prior guidance and ending the period with a robust cash and marketable securities balance sufficient to support operations through 2027.
2. Pipeline Advancement
The company reported that its lead immuno-neurology candidate progressed into Phase 1 clinical trials during the quarter, marking a significant milestone for its neurodegenerative disease research.
3. Cash Position
With the closing cash balance at quarter end, Prothena projects a runway extending into 2027, underpinned by disciplined R&D spending and overhead management.
4. New Collaboration
Prothena announced a new strategic collaboration focused on its amyloid-targeting platform, broadening its partnership network and unlocking additional research funding.